E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Postmenopausal Osteoporosis |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10031285 |
E.1.2 | Term | Osteoporosis postmenopausal |
E.1.2 | System Organ Class | 10028395 - Musculoskeletal and connective tissue disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1) To estimate the change from baseline (randomization in Protocol 004-02) in BMD at the lumbar spine at Years 8 and 10 with 50 mg of odanacatib once weekly in postmenopausal osteoporotic women previously treated for up to 5 years with odanacatib once weekly (in Protocols 004-02, 004-11, and 004-22). 2) To assess the safety of treatment with odanacatib 50 mg once weekly for up to 10 years.
|
|
E.2.2 | Secondary objectives of the trial |
1)To estimate change from baseline (randomization in Protocol 004-02) in BMD at the total hip, femoral neck, hip trochanter, and one-third distal radius with odanacatib 50 mg once weekly. 2) To estimate change from baseline (randomization in Protocol 004-02) on biochemical indices of bone resorption and biochemical indices of bone formation (serum bone-specific alkaline phosphatase [s-BSAP], serum N-terminal propeptide of Type 1 collagen [s-P1NP]) with odanacatib 50 mg once weekly. 3) To estimate change from Month 60 in Protocol 004-22 in BMD at the lumbar spine, total hip, femoral neck, hip trochanter, and one-third distal radius with odanacatib 50 mg once weekly. 4) To estimate change from Month 60 in Protocol 004-22 on biochemical indices of bone resorption (u-NTx, s-CTx, s TRAP 5b, s 1CTP) and biochemical indices of bone formation (s-BSAP, s-P1NP) with odanacatib 50 mg once weekly.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) Patient has met all initial inclusion criteria and has not met any of the exclusion criteria of Protocol 004-22. Note: There is no specific BMD T-score required for eligibility in this extension study at Visit 27 (Month 60) or at Visit 27E. Patients who meet excessive bone loss criteria at Visit 27 should be discontinued (see Section 3.2.3.6 for details). 2) Patient has participated in and completed 60 months of treatment in Protocols 004-02, 004-11, and 004-22 (to be determined at Visit 27/Month 60). 3) Patient is in generally good health, based on medical history, physical examination, and laboratory evaluation.
|
|
E.4 | Principal exclusion criteria |
A patient may not enter the extension study if: 1) Patient has withdrawn from Protocol 004-22 for any reason prior to completing 60 months of treatment. 2) Patient experienced a hip, spine, or other fragility fracture during the previous studies (004-02, 004-11 and 004-22) and would prefer to take other osteoporosis therapy (bisphosphonates or PTH) for which she is eligible. Note: A fragility fracture is defined as a vertebral or non-vertebral fracture, excluding fingers, toes, or skull, that occurs when a person falls from a standing height or less, or a fracture sustained without falling, such as a vertebral fracture following coughing; these fractures indicate reduced bone strength, as normal-strength bone should be able to withstand this degree of load. 3) Patient was diagnosed with primary parathyroid disease during the previous studies (004-02, 004-11 and 004-22) and has an elevated PTH or a serum calcium level greater than the upper limit of normal range. 4) Patient has hypocalcemia as defined as serum calcium <8.5 mg/dL, when corrected for albumin, or evidence of secondary hyperparathyroidism. 5) Patient has significant clinical or laboratory abnormalities at the baseline of this extension study (Visit 27/Month 60) that, in the opinion of the investigator, could complicate interpretation of the study results or pose additional risk to the patient (for example, patients who are non-ambulatory should be excluded for this reason). 6) Patient has cancer or had a diagnosis of any malignancy during the previous studies (004-02, 004-11 and 004-22), except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. 7) Patient is taking Vitamin A (excluding beta carotene) >10,000 IU daily or Vitamin D >5,000 IU daily. 8) Patient has received treatment that may have an effect on bone, including, but not limited to (refer to Appendix 6.6): a) Current use of chemotherapy or heparin b) Protease inhibitors for HIV treatment at any time c) Patient is taking anti-seizure medication, and indices of calcium metabolism are not within normal limits (Note: if serum calcium is within normal limits, the patient may enroll based on this criterion) 9) Current use of systemically administered azole antifungals (for example, systemic ketoconazole, fluconazole, itraconazole, miconazole, posaconozole, ravuconazole, and voriconazole) and other strong CYP3A4 inhibitors, such as clarithromycin and telithromycin (note: azithromycin is permitted). 10) Patient is currently treated with strong CYP3A4 inducers (e.g., rifampin [rifampicin], phenobarbital, barbiturates, carbamazepine, phenytoin, St. John's wort, nevirapine, efavirenz, and etravirine). 11) Patient is, in the opinion of the investigator, mentally or legally incapacitated such that informed consent cannot be obtained or the patient cannot read or comprehend the written material. 12) Patient has participated in an investigational drug study other than Protocol 004-22 within the past 30 days. 13) Patient is currently a user of recreational or illicit drugs or has had a recent history of drug or alcohol abuse or dependence. 14) Patient demonstrates noncompliance in following the procedures required in the study.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint will be the percent change from baseline in lumbar spine BMD |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 12 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The date the last subject completes the final visit. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 10 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 10 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |